Literature DB >> 26392503

Substitutions at NS3 Residue 155, 156, or 168 of Hepatitis C Virus Genotypes 2 to 6 Induce Complex Patterns of Protease Inhibitor Resistance.

Sanne B Jensen1, Stéphanie B N Serre1, Daryl G Humes1, Santseharay Ramirez1, Yi-Ping Li1, Jens Bukh1, Judith M Gottwein2.   

Abstract

Various protease inhibitors (PIs) currently are becoming available for treatment of hepatitis C virus (HCV). For genotype 1, substitutions at NS3 protease positions 155, 156, and 168 are the main determinants of PI resistance. For other genotypes, similar substitutions were selected during PI treatment but were not characterized systematically. To elucidate the impact of key PI resistance substitutions on genotypes 2 to 6, we engineered the substitutions R155A/E/G/H/K/Q/T, A156G/S/T/V, and D/Q168A/E/G/H/N/V into HCV recombinants expressing genotype 2 to 6 proteases. We evaluated viral fitness and sensitivity to nine PIs (telaprevir, boceprevir, simeprevir, asunaprevir, vaniprevir, faldaprevir, paritaprevir, deldeprevir, and grazoprevir) in Huh7.5 cells. We found that most variants showed decreased fitness compared to that of the original viruses. Overall, R155K, A156G/S, and D/Q168A/E/H/N/V variants showed the highest fitness; however, genotype 4 position 168 variants showed strong fitness impairment. Most variants tested were resistant to several PIs. Resistance levels varied significantly depending on the specific substitution, genotype, and PI. For telaprevir and boceprevir, specific 155 and 156, but not 168, variants proved resistant. For the remaining PIs, most genotype 2, 4, 5, and 6, but not genotype 3, variants showed various resistance levels. Overall, grazoprevir (MK-5172) had the highest efficacy against original viruses and variants. This is the first comprehensive study revealing the impact of described key PI resistance substitutions on fitness and PI resistance of HCV genotypes 2 to 6. In conclusion, the studied substitutions induced resistance to a panel of clinically relevant PIs, including the newer PIs paritaprevir, deldeprevir, and grazoprevir. We discovered complex patterns of resistance, with the impact of substitutions varying from increased sensitivity to high resistance.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26392503      PMCID: PMC4649233          DOI: 10.1128/AAC.01953-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  58 in total

Review 1.  The role of resistance in HCV treatment.

Authors:  Johannes Vermehren; Christoph Sarrazin
Journal:  Best Pract Res Clin Gastroenterol       Date:  2012-08       Impact factor: 3.043

2.  Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus.

Authors:  Tetsuro Shimakami; Christoph Welsch; Daisuke Yamane; David R McGivern; Minkyung Yi; Stefan Zeuzem; Stanley M Lemon
Journal:  Gastroenterology       Date:  2010-11-04       Impact factor: 22.682

3.  Selection of clinically relevant protease inhibitor-resistant viruses using the genotype 2a hepatitis C virus infection system.

Authors:  Guofeng Cheng; Katie Chan; Huiling Yang; Amy Corsa; Maria Pokrovskii; Matthew Paulson; Gina Bahador; Weidong Zhong; William Delaney
Journal:  Antimicrob Agents Chemother       Date:  2011-02-28       Impact factor: 5.191

4.  In vivo study of the HC-TN strain of hepatitis C virus recovered from a patient with fulminant hepatitis: RNA transcripts of a molecular clone (pHC-TN) are infectious in chimpanzees but not in Huh7.5 cells.

Authors:  Akito Sakai; Shingo Takikawa; Robert Thimme; Jean-Christophe Meunier; Hans Christian Spangenberg; Sugantha Govindarajan; Patrizia Farci; Suzanne U Emerson; Francis V Chisari; Robert H Purcell; Jens Bukh
Journal:  J Virol       Date:  2007-04-04       Impact factor: 5.103

5.  Efficacy and safety of simeprevir with PegIFN/ribavirin in naïve or experienced patients infected with chronic HCV genotype 4.

Authors:  Christophe Moreno; Christophe Hezode; Patrick Marcellin; Stefan Bourgeois; Sven Francque; Didier Samuel; Fabien Zoulim; Jean-Didier Grange; Umesh Shukla; Oliver Lenz; Sivi Ouwerkerk-Mahadevan; Bart Fevery; Monika Peeters; Maria Beumont; Wolfgang Jessner
Journal:  J Hepatol       Date:  2015-01-14       Impact factor: 25.083

Review 6.  The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report.

Authors:  Nabil Antaki; Antonio Craxi; Sanaa Kamal; Rami Moucari; Schalk Van der Merwe; Samir Haffar; Adrian Gadano; Nizar Zein; Ching Lung Lai; Jean-Michel Pawlotsky; E Jenny Heathcote; Geoffrey Dusheiko; Patrick Marcellin
Journal:  Liver Int       Date:  2009-12-10       Impact factor: 5.828

7.  Exploratory trial of ombitasvir and ABT-450/r with or without ribavirin for HCV genotype 1, 2, and 3 infection.

Authors:  Eric Lawitz; Greg Sullivan; Maribel Rodriguez-Torres; Michael Bennett; Fred Poordad; Mudra Kapoor; Prajakta Badri; Andrew Campbell; Lino Rodrigues; Yiran Hu; Tami Pilot-Matias; Regis A Vilchez
Journal:  J Infect       Date:  2014-09-22       Impact factor: 6.072

Review 8.  Hepatitis C virus proteins: from structure to function.

Authors:  Darius Moradpour; François Penin
Journal:  Curr Top Microbiol Immunol       Date:  2013       Impact factor: 4.291

9.  Efficacy of telaprevir-based therapy for difficult-to-treat patients with genotype 2 chronic hepatitis C in Japan.

Authors:  Hiromitsu Kumada; Ken Sato; Tetsuo Takehara; Makoto Nakamuta; Masatoshi Ishigami; Kazuaki Chayama; Joji Toyota; Fumitaka Suzuki; Yoshiyuki Nakayasu; Miyoko Ochi; Ichimaro Yamada; Takeshi Okanoue
Journal:  Hepatol Res       Date:  2014-11-18       Impact factor: 4.288

10.  Differential sensitivity of 5'UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors.

Authors:  Yi-Ping Li; Santseharay Ramirez; Daryl Humes; Sanne B Jensen; Judith M Gottwein; Jens Bukh
Journal:  Gastroenterology       Date:  2013-11-18       Impact factor: 22.682

View more
  10 in total

Review 1.  KASL clinical practice guidelines: management of hepatitis C.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2016-03-28

2.  Hepatitis C Virus Genotype 1 to 6 Protease Inhibitor Escape Variants: In Vitro Selection, Fitness, and Resistance Patterns in the Context of the Infectious Viral Life Cycle.

Authors:  Stéphanie B N Serre; Sanne B Jensen; Lubna Ghanem; Daryl G Humes; Santseharay Ramirez; Yi-Ping Li; Henrik Krarup; Jens Bukh; Judith M Gottwein
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

Review 3.  Resistance detection and re-treatment options in hepatitis C virus-related chronic liver diseases after DAA-treatment failure.

Authors:  Evangelista Sagnelli; Mario Starace; Carmine Minichini; Mariantonietta Pisaturo; Margherita Macera; Caterina Sagnelli; Nicola Coppola
Journal:  Infection       Date:  2018-08-06       Impact factor: 3.553

4.  Molecular and Dynamic Mechanism Underlying Drug Resistance in Genotype 3 Hepatitis C NS3/4A Protease.

Authors:  Djadé I Soumana; Nese Kurt Yilmaz; Akbar Ali; Kristina L Prachanronarong; Celia A Schiffer
Journal:  J Am Chem Soc       Date:  2016-09-02       Impact factor: 15.419

5.  Efficient Hepatitis C Virus Genotype 1b Core-NS5A Recombinants Permit Efficacy Testing of Protease and NS5A Inhibitors.

Authors:  Long V Pham; Santseharay Ramirez; Thomas H R Carlsen; Yi-Ping Li; Judith M Gottwein; Jens Bukh
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

6.  Antiviral Activity and Resistance Analysis of NS3/4A Protease Inhibitor Grazoprevir and NS5A Inhibitor Elbasvir in Hepatitis C Virus GT4 Replicons.

Authors:  Ernest Asante-Appiah; Stephanie Curry; Patricia McMonagle; Paul Ingravallo; Robert Chase; David Nickle; Ping Qiu; Anita Howe; Frederick C Lahser
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.938

7.  In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS3/4A Protease Inhibitor Glecaprevir.

Authors:  Teresa I Ng; Rakesh Tripathi; Thomas Reisch; Liangjun Lu; Timothy Middleton; Todd A Hopkins; Ron Pithawalla; Michelle Irvin; Tatyana Dekhtyar; Preethi Krishnan; Gretja Schnell; Jill Beyer; Keith F McDaniel; Jun Ma; Guoqiang Wang; Li-Juan Jiang; Yat Sun Or; Dale Kempf; Tami Pilot-Matias; Christine Collins
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

Review 8.  Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape Variants.

Authors:  Sanne Brun Jensen; Ulrik Fahnøe; Long V Pham; Stéphanie Brigitte Nelly Serre; Qi Tang; Lubna Ghanem; Martin Schou Pedersen; Santseharay Ramirez; Daryl Humes; Anne Finne Pihl; Jonathan Filskov; Christina Søhoel Sølund; Julia Dietz; Slim Fourati; Jean-Michel Pawlotsky; Christoph Sarrazin; Nina Weis; Kristian Schønning; Henrik Krarup; Jens Bukh; Judith Margarete Gottwein
Journal:  Hepatology       Date:  2019-06-05       Impact factor: 17.425

9.  Geno2pheno[HCV] - A Web-based Interpretation System to Support Hepatitis C Treatment Decisions in the Era of Direct-Acting Antiviral Agents.

Authors:  Prabhav Kalaghatgi; Anna Maria Sikorski; Elena Knops; Daniel Rupp; Saleta Sierra; Eva Heger; Maria Neumann-Fraune; Bastian Beggel; Andreas Walker; Jörg Timm; Hauke Walter; Martin Obermeier; Rolf Kaiser; Ralf Bartenschlager; Thomas Lengauer
Journal:  PLoS One       Date:  2016-05-19       Impact factor: 3.240

10.  Small molecule degraders of the hepatitis C virus protease reduce susceptibility to resistance mutations.

Authors:  Mélissanne de Wispelaere; Guangyan Du; Katherine A Donovan; Tinghu Zhang; Nicholas A Eleuteri; Jingting C Yuan; Joann Kalabathula; Radosław P Nowak; Eric S Fischer; Nathanael S Gray; Priscilla L Yang
Journal:  Nat Commun       Date:  2019-08-01       Impact factor: 14.919

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.